Symbols

CRMD

CorMedix·NASDAQ

--(--)

CRMD fundamentals

CRMD Q4 2025 Earnings

CorMedix (CRMD) released its earnings on Mar 5, 2026: revenue was 128.60M (YoY +312.05%), beat estimates; EPS was 0.16 (YoY -27.27%), missed estimates.

Revenue / YoY

128.60M

+312.05%

EPS / YoY

0.16

-27.27%

Report date

Mar 5, 2026

CRMD Earnings Call Summary for Q4,2025

2025 Milestones: $258.8M DefenCath sales, $35M Melinta synergies, and $401.3M pro forma revenue.
2026 Outlook: $150-170M DefenCath, $300-320M revenue, $100-125M EBITDA; front-loaded with Q3/Q4 price erosion.
Pipeline Catalysts: REZZAYO Phase III data Q2 2026, DefenCath TPN study 2027 completion.
Financial Strength: $148.5M cash, 200+ employees, and $77.2M adj EBITDA in Q4.
Strategic Moves: Share buybacks, Medicare Advantage contracting, and TDAPA legislative advocacy.

Earnings

EPS

Revenue

Revenue & Expenses

CRMD has released its 2025 Q4 earnings report, with revenue of 128.62M, reflecting a YoY change of 312.10%, and net profit of 14.02M, showing a YoY change of 4.13%. The Sankey diagram below clearly presents CRMD's revenue sources and cost distribution.

Key Indicators

CorMedix (CRMD) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

CorMedix (CRMD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

CorMedix (CRMD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

CorMedix (CRMD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown